0.2510
+0.0410
+(19.52%)
At close: January 10 at 4:00:00 PM EST
0.2559
+0.00
+(1.95%)
After hours: 7:56:12 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Uzi Sofer | CEO & Chairman | 630k | -- | 1970 |
Mr. Raphi Levy | Chief Financial Officer | 424k | -- | 1985 |
Mr. Amnon Gat | Chief Operations Officer | 340k | -- | 1975 |
Mr. Peter M. Melnyk | Chief Commercial Officer | 376k | -- | 1962 |
Dr. Robert B. Den M.D. | Chief Medical Officer & Member of Scientific Advisory Board | 401k | -- | 1979 |
Mr. Ronen Segal | Chief Technology Officer | 380k | -- | 1973 |
Prof. Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board | -- | -- | 1947 |
Ms. Rebecca Becker | Vice President of legal | -- | -- | -- |
Prof. Itzhak Kelson | Chief Physics Officer & Member of Scientific Advisory Board | -- | -- | 1940 |
Ms. Yael Zeiger | Corporate Controller | -- | -- | 1983 |
Alpha Tau Medical Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 121
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Corporate Governance
Alpha Tau Medical Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
4GB.F Gossamer Bio, Inc.
0.9525
-2.01%
SRZNW Surrozen, Inc.
0.0500
0.00%
W1H.F Onco-Innovations Limited
0.8220
-4.08%
ABPWW Abpro Holdings Inc
0.0635
-23.49%
KTTAW Pasithea Therapeutics Corp.
0.0251
0.00%
BST.MC Biotechnology Assets, S.A.
0.3090
+1.31%
NLSPW NLS Pharmaceutics AG
0.0162
-6.36%
ONCO.CN Onco-Innova
1.2000
0.00%
BCTXW BriaCell Therapeutics Corp.
0.1600
-17.91%
ACTU Actuate Therapeutics, Inc. Common stock
8.30
+3.75%